Global Oncology Academy

DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
- Ryan Quigley
- David F. McDermott, MD
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
- Aline Fares, MD
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
- Richard Kim, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Global Oncology Academy
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
- Wayne Kuang, MD
- William Oh, MD
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
- Jorge Nieva, MD
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome

Medical News

Medical News
Leveraging AI for Enhanced Diagnosis of Endocrine Cancers Amid Rising Obesity-Related Incidences
07/15/2025
Read more
Medical News
The Emerging Role of Tirzepatide in Obesity-Related Breast Cancer
07/15/2025
Read more
Medical News
Integrating Weight Management and Oncology: Navigating Immune Challenges Post-Weight Loss
07/14/2025
Read more
Medical News
Emerging Roles of Hydrogel-Conjugated Drug Delivery in Cancer Therapy
07/14/2025
Read more

See more news

CME/CE

First-line Chemotherapy Options in Metastatic PDAC
First-line Chemotherapy Options in Metastatic PDAC
MinuteCE®
First-line Chemotherapy Options in Metastatic PDAC
0.25 program credits
- Eileen O’Reilly, MD
0.25 program credits
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
MinuteCE®
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
1.00 credit 5 episodes
- Jenny Seligmann, MBChB, PhD
- Fortunato Ciardiello, MD, PhD
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 credit 5 episodes

Clinical Practice

Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Clinician's Roundtable
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
- Charles Turck, PharmD, BCPS, BCCCP
- Brennan Spiegel, MD, MSHS
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
Clinician's Roundtable
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Muench, MD
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Project Oncology®
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
- Charles Turck, PharmD, BCPS, BCCCP
- Richard Kim, MD
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
- Jorge Nieva, MD

Programs

Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Lunning, DO, FACP
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
- Jorge Nieva, MD
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
- Vanessa Helou, MD